Molecules that bind to cd94/nkg2a heterodimer polypeptides
US-2024415889-A1 · Dec 19, 2024 · US
Bispecific antibodies binding ALK-1 and BMPR-2
US11292846B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11292846-B2 |
| Application number | US-201816760704-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 25, 2018 |
| Priority date | Nov 2, 2017 |
| Publication date | Apr 5, 2022 |
| Grant date | Apr 5, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Bispecific antibodies binding ALK-1 and BMPR-2 The present invention relates to bispecific antibodies binding human ALK-1 and human BMPR-2. Also provided are BsABs which are agonists of ALK-1/BMPR-2 signaling, and BsABs which do not trigger osteogenic signaling. Furthermore, the invention relates to pharmaceutical uses of the BsABs, in particular for the treatment of pulmonary hypertension. Also provided are methods to screen for BsABs for use in the therapy, e.g. of pulmonary hypertension.
First claim
Opening claim text (preview).
The invention claimed is: 1. A bispecific antibody (BsAB), wherein said BsAB comprises an ALK-1 binding domain and a BMPR-2 binding domain, wherein said BsAB promotes dimerization of ALK-1 and BMPR-2, and wherein said BsAB is TPP-14696 comprising the amino acid sequences of SEQ ID NOS: 1, 8, 15, and 22 or TPP-14719 comprising the amino acid sequences of SEQ ID NOS: 29, 36, 43, and 50. 2. A BsAB according to claim 1 , wherein the ALK-1 is human ALK-1 or a fragment thereof, and wherein the BMPR-2 is human BMPR-2 or a fragment thereof.
Assignees
Inventors
Classifications
Single chain antibody (scFv) · CPC title
Drugs for disorders of the blood or the extracellular fluid · CPC title
comprising antibodies · CPC title
- C07K16/2863Primary
against receptors for growth factors, growth regulators · CPC title
multispecific · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11292846B2 cover?
- Bispecific antibodies binding ALK-1 and BMPR-2 The present invention relates to bispecific antibodies binding human ALK-1 and human BMPR-2. Also provided are BsABs which are agonists of ALK-1/BMPR-2 signaling, and BsABs which do not trigger osteogenic signaling. Furthermore, the invention relates to pharmaceutical uses of the BsABs, in particular for the treatment of pulmonary hypertension. Als…
- Who is the assignee on this patent?
- Bayer Ag
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2863. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).